Telix Pharmaceuticals Ltd
Illuccix
prostate cancer imaging
Resolved
168days ago
FDA decision · Jan 20, 2026
What's at stake
The FDA's approval decision on Illuccix for prostate cancer imaging is due Jan 20, 2026. A green light opens the market; a complete response letter (CRL) usually sinks the stock.
Primary source
· SEC 6-K
verified 12h ago
“Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces that the Chinese National Medical Products Administration (NMPA) Center for Drug Evaluation (CDE) has accepted the filing of a New Drug Application (NDA) for TLX”